Cargando…

Pooled Analysis of Baricitinib Tolerability in Patients With Atopic Dermatitis in Relation to Acne, Headache, and Gastrointestinal Events From 8 Clinical Trials

ABSTRACT: BACKGROUND: Tolerability issues including acne, nausea, and headache have been reported with Janus kinase (JAK) inhibitors for moderate-to-severe atopic dermatitis (AD). OBJECTIVES: To report outcomes of tolerability adverse events (AEs) for baricitinib, a JAK1/JAK2 inhibitor, in patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wollenberg, Andreas, Kircik, Leon, Simpson, Eric, Brinker, Dennis, Katoh, Norito, Rueda, Maria Jose, Issa, Maher, Yang, Fan, Feely, Meghan, Alexis, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc., publishers 2023
Materias:	Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357532/ https://www.ncbi.nlm.nih.gov/pubmed/36749121 http://dx.doi.org/10.1089/derm.2022.0027

Ejemplares similares

Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials
por: Katoh, Norito, et al.
Publicado: (2022)

Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials
por: King, Brett, et al.
Publicado: (2021)

Clinical Tailoring of Baricitinib 2 mg in Atopic Dermatitis: Baseline Body Surface Area and Rapid Onset of Action Identifies Response at Week 16
por: Silverberg, Jonathan I., et al.
Publicado: (2021)

Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Atopic Dermatitis: Identification and Management of Complicating Factors
por: Tamagawa-Mineoka, Risa, et al.
Publicado: (2020)

Treatment of Atopic Dermatitis with Baricitinib: First Real-life Experience
por: ROGNER, Danielle, et al.
Publicado: (2022)

Correction to: Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials
por: Simpson, Eric L., et al.
Publicado: (2023)

Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial
por: Reich, Kristian, et al.
Publicado: (2020)

Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate‐to‐severe atopic dermatitis from the BREEZE‐AD7 Phase 3 randomized trial
por: Wollenberg, A., et al.
Publicado: (2021)

Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
por: Nogueira, Miguel, et al.
Publicado: (2021)

Baricitinib Lipid-Based Nanosystems as a Topical Alternative for Atopic Dermatitis Treatment
por: Garrós, Núria, et al.
Publicado: (2023)

Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
por: de Bruin-Weller, Marjolein S., et al.
Publicado: (2022)

Exploratory analyses of biomarkers in blood and stratum corneum in patients with atopic dermatitis
por: Maruyama, Ayano, et al.
Publicado: (2022)

Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib
por: Nezamololama, Novin, et al.
Publicado: (2020)

Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials
por: Silverberg, Jonathan I., et al.
Publicado: (2021)

The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trials
por: Yosipovitch, Gil, et al.
Publicado: (2022)

Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16
por: Thyssen, Jacob P., et al.
Publicado: (2023)

Developing integrated care pathways for atopic dermatitis—Challenges and unmet needs
por: Zuberbier, Torsten, et al.
Publicado: (2023)

Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS‐J): Baseline characteristics, treatment history and disease burden
por: Katoh, Norito, et al.
Publicado: (2019)

Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients
por: Radi, Giulia, et al.
Publicado: (2021)

Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate‐to‐severe atopic dermatitis: A network meta‐analysis
por: Wan, Huiying, et al.
Publicado: (2022)

Acne Vulgaris, Atopic Dermatitis and Rosacea: The Role of the Skin Microbiota—A Review
por: Condrò, Giorgia, et al.
Publicado: (2022)

Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis
por: Eichenfield, Lawrence F., et al.
Publicado: (2019)

Prevention of atopic dermatitis
por: Williams, Hywel C., et al.
Publicado: (2012)

Profile of Baricitinib and Its Potential in the Treatment of Moderate to Severe Atopic Dermatitis: A Short Review on the Emerging Clinical Evidence
por: Napolitano, Maddalena, et al.
Publicado: (2020)

Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies
por: Buhl, Timo, et al.
Publicado: (2021)

Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry
por: BOESJES, Celeste M., et al.
Publicado: (2022)

The Treat-to-Target Project in Atopic Dermatitis: One Year On
por: DE BRUIN-WELLER, Marjolein, et al.
Publicado: (2023)

The Impact of Acne, Atopic Dermatitis, Skin Toxicities and Scars on Quality of Life and the Importance of a Holistic Treatment Approach
por: Dreno, Brigitte, et al.
Publicado: (2021)

A case series of acne following Janus kinase inhibitors in patients with atopic dermatitis
por: Lee, Sang-Doo, et al.
Publicado: (2022)

Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis
por: WOLLENBERG, Andreas, et al.
Publicado: (2022)

Difficult to control atopic dermatitis
por: Darsow, Ulf, et al.
Publicado: (2013)

Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry
por: BOESJES, Celeste M., et al.
Publicado: (2023)

How to Understand Personalized Medicine in Atopic Dermatitis Nowadays?
por: Mesjasz, Alicja, et al.
Publicado: (2023)

Acne keloidalis nuchae in a patient with atopic dermatitis treated with Janus kinase inhibitor upadacitinib
por: Caudrelier, Nicolas, et al.
Publicado: (2023)

Assessing the Accuracy and Comprehensiveness of ChatGPT in Offering Clinical Guidance for Atopic Dermatitis and Acne Vulgaris
por: Lakdawala, Nehal, et al.
Publicado: (2023)

Racial and Ethnic Differences in Sociodemographic, Clinical, and Treatment Characteristics Among Patients with Atopic Dermatitis in the United States and Canada: Real-World Data from the CorEvitas Atopic Dermatitis Registry
por: Silverberg, Jonathan I., et al.
Publicado: (2023)

Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis—A pooled analysis of trial data
por: Paller, Amy S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4hcfmm08ubhep9373b9mr04nhj